DV Trading LLC Takes $2 Million Position in Eupraxia Pharmaceuticals Inc. $EPRX

DV Trading LLC purchased a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 276,000 shares of the company’s stock, valued at approximately $1,998,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC lifted its holdings in Eupraxia Pharmaceuticals by 429.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after buying an additional 1,289,005 shares in the last quarter. Vivo Capital LLC purchased a new position in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $7,965,000. Redmile Group LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the first quarter valued at about $5,068,000. Rubric Capital Management LP acquired a new stake in shares of Eupraxia Pharmaceuticals during the first quarter valued at about $5,004,000. Finally, Ally Bridge Group NY LLC increased its position in shares of Eupraxia Pharmaceuticals by 66.0% during the first quarter. Ally Bridge Group NY LLC now owns 660,375 shares of the company’s stock worth $4,781,000 after acquiring an additional 262,480 shares during the last quarter.

Eupraxia Pharmaceuticals Price Performance

Shares of EPRX stock opened at $6.40 on Friday. The firm has a fifty day moving average of $6.47 and a two-hundred day moving average of $7.29. The firm has a market cap of $416.13 million, a P/E ratio of -6.10 and a beta of 1.05. Eupraxia Pharmaceuticals Inc. has a 1-year low of $5.04 and a 1-year high of $9.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 19.31 and a quick ratio of 19.31.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, research analysts anticipate that Eupraxia Pharmaceuticals Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on EPRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Oppenheimer began coverage on Eupraxia Pharmaceuticals in a report on Thursday, June 25th. They set an “outperform” rating and a $17.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Finally, Stifel Nicolaus began coverage on Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They set a “buy” rating and a $25.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eupraxia Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $18.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.